Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@thelancetendo.bsky.socialOct 9, 2026, 8:11 AM

Sten Madsbad & Jens J Holst comment on:
#Petrelintide and the evolving role of #amylin agonism in #obesity thelancet.com/journals/lan...
#FREE to read w/reg (also FREE)

#MedSky #EndoSky

@thelancetendo.bsky.socialOct 9, 2026, 8:11 AM

#Petrelintide is a novel, long-acting #amylin analogue being developed for long-term treatment of #obesity, leveraging a mechanism of action distinct from incretin-based treatments thelancet.com/journals/lan...
#FREE to read w/reg (also FREE)

#MedSky #EndoSky

@midgardfinance.comOct 8, 2026, 7:45 AM

💉 #pharma #obesity #petrelintide $ZEAL 🇩🇰 $RO 🇨🇭
Petrelintide in type 2 diabetes: 7.4-9.2% weight loss at week 28 vs 2.0% on placebo (#ZUPREME-2, Phase 2, 220 people).
Without diabetes: 7.9-9.8% at the same week. HbA1c fell by up to 0.65 points.
midgardfinance.com/obesity/drugs/petrelintide/

Grouped bar chart of average weight change at week 28 in two phase 2 trials of petrelintide, Zealand Pharma's weekly amylin injection partnered with Roche. Left group, ZUPREME-1 in people without diabetes: placebo -1.7 per cent, the dose that lost least -7.9 per cent, the dose that lost most -9.8 per cent. Right group, ZUPREME-2 in people with type 2 diabetes, topline of 7 October 2026: placebo -2.0 per cent, the dose that lost least -7.4 per cent, the dose that lost most -9.2 per cent. The two groups look almost the same: weight loss in people with diabetes is about half a point smaller. ZUPREME-2 has not named its three doses. Figures are for patients who stayed on treatment.
@midgardfinance.comSep 30, 2026, 3:00 PM

💉 #obesity #EASD2026

🇩🇰 Zealand's #petrelintide, partnered with 🇨🇭 Roche, Phase 2 ZUPREME-1 in The Lancet Diabetes & Endocrinology, week 42:

1 mg: -8.7%
5 mg: -10.7%
9 mg: -10.2%
Placebo: -1.7%

Nine times the dose adds 1.5 points. Vomiting 3%, below placebo's 6%.

$ZEAL $RO

Bar chart of average weight change at week 42 in the phase 2 ZUPREME-1 trial of petrelintide, Zealand Pharma's weekly amylin injection partnered with Roche, published in The Lancet Diabetes and Endocrinology on 29 September 2026. One grey bar for placebo and five blue bars for the weekly doses: placebo -1.7 per cent, 1 mg -8.7 per cent, 2.5 mg -9.2 per cent, 5 mg -10.7 per cent, 7 mg -10.5 per cent, 9 mg -10.2 per cent. The five dose bars are almost the same height: the lowest dose loses 8.7 per cent and the highest 10.2 per cent, and the deepest arm is 5 mg, not the top dose. Figures are for patients who stayed on treatment.